Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
KALARIS THERAPEUTICS INC (KLRS) Stock Price & Overview
NASDAQ:KLRS • US4829291065
Current stock price
5.46 USD
-0.06 (-1.09%)
At close:
5.4002 USD
-0.06 (-1.1%)
After Hours:
The current stock price of KLRS is 5.46 USD. Today KLRS is down by -1.09%. In the past month the price decreased by -5.7%. In the past year, price decreased by -6.35%.
KLRS Key Statistics
52-Week Range2.14 - 11.88
Current KLRS stock price positioned within its 52-week range.
1-Month Range5.42 - 7.14
Current KLRS stock price positioned within its 1-month range.
- Market Cap
- 125.198M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.28
- Dividend Yield
- N/A
KLRS Stock Performance
Today
-1.09%
1 Week
-10.64%
1 Month
-5.70%
3 Months
-38.51%
Longer-term
6 Months +8.55%
1 Year -6.35%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
KLRS Stock Chart
KLRS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to KLRS. When comparing the yearly performance of all stocks, KLRS is a bad performer in the overall market: 87.24% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
KLRS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KLRS. KLRS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
KLRS Earnings
Next Earnings DateMay 20, 2026
Last Earnings DateMar 17, 2026
PeriodQ4 / 2025
EPS Reported-$0.51
Revenue Reported
EPS Surprise 5.93%
Revenue Surprise %
KLRS Forecast & Estimates
12 analysts have analysed KLRS and the average price target is 19.38 USD. This implies a price increase of 254.95% is expected in the next year compared to the current price of 5.46.
Analysts
Analysts85
Price Target19.38 (254.95%)
EPS Next Y46.7%
Revenue Next YearN/A
KLRS Index Membership
KLRS is currently included in the following stock indexes tracked on ChartMill.
KLRS Financial Highlights
Over the last trailing twelve months KLRS reported a non-GAAP Earnings per Share(EPS) of -4.28. The EPS increased by 49.83% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-43.44M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.68% | ||
| ROE | -55.11% | ||
| Debt/Equity | 0.41 |
Chartmill High Growth Momentum
EPS Q2Q%85.87%
Sales Q2Q%N/A
EPS 1Y (TTM)49.83%
Revenue 1Y (TTM)N/A
KLRS Ownership
Ownership
Inst Owners78.86%
Shares22.93M
Float20.58M
Ins Owners4.79%
Short Float %4.09%
Short Ratio11.87
KLRS Industry Overview
KLRS operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
KLRS Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KLRS
Company Profile
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Company Info
IPO: 2020-07-30
KALARIS THERAPEUTICS INC
400 Connell Drive, Suite 5500
Berkeley Heights NEW JERSEY US
Employees: 20
Phone: 16502492727
KALARIS THERAPEUTICS INC / KLRS FAQ
What does KALARIS THERAPEUTICS INC do?
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
What is the stock price of KALARIS THERAPEUTICS INC today?
The current stock price of KLRS is 5.46 USD. The price decreased by -1.09% in the last trading session.
Does KALARIS THERAPEUTICS INC pay dividends?
KLRS does not pay a dividend.
What is the ChartMill technical and fundamental rating of KLRS stock?
KLRS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is KLRS stock listed?
KLRS stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of KLRS stock?
KALARIS THERAPEUTICS INC (KLRS) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for KALARIS THERAPEUTICS INC?
KALARIS THERAPEUTICS INC (KLRS) has a market capitalization of 125.20M USD. This makes KLRS a Micro Cap stock.